Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Garcia, Giani Martins | - |
Autor(es): dc.creator | Oliveira, Liliam Teixeira | - |
Autor(es): dc.creator | Pitta, Ivan da Rocha | - |
Autor(es): dc.creator | Lima, Maria do Carmo Alves de | - |
Autor(es): dc.creator | Vilela, José Mário Carneiro | - |
Autor(es): dc.creator | Andrade, Margareth Spangler | - |
Autor(es): dc.creator | Abdalla, Dulcinéia Saes Parra | - |
Autor(es): dc.creator | Mosqueira, Carla Furtado | - |
Data de aceite: dc.date.accessioned | 2019-11-06T13:36:02Z | - |
Data de disponibilização: dc.date.available | 2019-11-06T13:36:02Z | - |
Data de envio: dc.date.issued | 2016-01-05 | - |
Data de envio: dc.date.issued | 2016-01-05 | - |
Data de envio: dc.date.issued | 2015 | - |
Fonte completa do material: dc.identifier | http://www.repositorio.ufop.br/handle/123456789/5988 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/559091 | - |
Descrição: dc.description | Wereport the in vitro release profile and comparative pharmacokinetics and biodistribution of a newperoxisome proliferator-activated receptor-γ agonist and cyclooxygenase inhibitor (Lyso-7) free or associated to poly(D,Llactic acid) nanocapsules (NC) after intravenous administration in mice. Lyso-7 pertains to the class of insulinsensitizing agents that shows potential beneficial effects in diabetes therapy. Monodispersed Lyso-7 NC with a mean diameter of 273 nm with high encapsulation efficiency (83%) were obtained. Lyso-7 dissolution rate was reduced (2.6-fold) upon loading in NC. The pharmacokinetic parameters were determined using a noncompartmental approach. In comparison with Lyso-7 in solution, the plasma-AUC increased 14-fold, the mean residence time 2.6-fold and the mean half-life (t1/2) 1.5-fold for Lyso-7-NC; the Lyso-7 plasma clearance, distribution volume and elimination rate were reduced 13, 10 and 1.4 fold, respectively, which indicates higher retention of encapsulated Lyso-7 in the blood compartment. Upon association with NC, organ exposure to Lyso-7 was higher in the heart (3.6-fold), lung (2.8-fold), spleen (2.3-fold), kidney (2-fold) and liver (1.8-fold) compared to Lyso-7 in solution. The analysis of whole data clearly indicates that body exposure to Lyso-7 was enhanced and the general toxicity reduced upon nanoencapsulation, allowing further evaluation of Lyso-7 in nonclinical and clinical studies | - |
Idioma: dc.language | en | - |
Direitos: dc.rights | O Periódico Journal of Controlled Release concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3732420794007 | - |
Palavras-chave: dc.subject | Thiazolidinedione | - |
Palavras-chave: dc.subject | Pharmacokinetics | - |
Título: dc.title | Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation. | - |
Aparece nas coleções: | Repositório Institucional - UFOP |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: